{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,17]],"date-time":"2026-05-17T02:14:48Z","timestamp":1778984088093,"version":"3.51.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T00:00:00Z","timestamp":1621382400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2021,8,3]]},"DOI":"10.1038\/s41416-021-01434-6","type":"journal-article","created":{"date-parts":[[2021,5,19]],"date-time":"2021-05-19T06:02:38Z","timestamp":1621404158000},"page":"402-412","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["A nomogram prognostic index for risk-stratification in diffuse large B-cell lymphoma in the rituximab era: a multi-institutional cohort study"],"prefix":"10.1038","volume":"125","author":[{"given":"Jun","family":"Cai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaopeng","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuyun","family":"Ma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liye","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wenyu","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6140-914X","authenticated-orcid":false,"given":"Liang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Linlang","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhihua","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guangzheng","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Huiqiang","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongjun","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi","family":"Xia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Panpan","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Su","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuchen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qingqing","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,5,19]]},"reference":[{"key":"1434_CR1","doi-asserted-by":"publisher","first-page":"443","DOI":"10.3322\/caac.21357","volume":"66","author":"LR Teras","year":"2016","unstructured":"Teras, L. R., DeSantis, C. E., Cerhan, J. R., Morton, L. M., Jemal, A. & Flowers, C. R. 2016 US lymphoid malignancy statistics by World Health Organization subtypes. CA Cancer J. Clin. 66, 443\u2013459 (2016).","journal-title":"CA Cancer J. Clin."},{"key":"1434_CR2","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-018-0308-x","author":"X Gu","year":"2018","unstructured":"Gu, X., Zheng, R., Xia, C., Zeng, H., Zhang, S., Zou, X. et al. Interactions between life expectancy and the incidence and mortality rates of cancer in China: a population-based cluster analysis. Cancer Commun. https:\/\/doi.org\/10.1186\/s40880-018-0308-x (2018).","journal-title":"Cancer Commun."},{"key":"1434_CR3","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1016\/S1470-2045(11)70235-2","volume":"12","author":"M Pfreundschuh","year":"2011","unstructured":"Pfreundschuh, M., Kuhnt, E., Trumper, L., Osterborg, A., Trneny, M., Shepherd, L. et al. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group. Lancet Oncol. 12, 1013\u20131022 (2011).","journal-title":"Lancet Oncol."},{"key":"1434_CR4","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","volume":"116","author":"B Coiffier","year":"2010","unstructured":"Coiffier, B., Thieblemont, C., Van Den Neste, E., Lepeu, G., Plantier, I., Castaigne, S. et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d\u2019Etudes des Lymphomes de l\u2019Adulte. Blood 116, 2040\u20132045 (2010).","journal-title":"Blood"},{"key":"1434_CR5","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJM199309303291402","volume":"329","author":"MA Shipp","year":"1993","unstructured":"Shipp, M. A., Harrington, D. P., Anderson, J. R., Armitage, J. O., Bonadonna, G., Brittinger, G. et al. A predictive model for aggressive non-Hodgkins-lymphoma. N. Engl. J. Med. 329, 987\u2013994 (1993).","journal-title":"N. Engl. J. Med."},{"key":"1434_CR6","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1182\/blood-2013-09-524108","volume":"123","author":"Z Zhou","year":"2014","unstructured":"Zhou, Z., Sehn, L. H., Rademaker, A. W., Gordon, L. I., LaCasce, A. S., Crosby-Thompson, A. et al. An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood 123, 837\u2013842 (2014).","journal-title":"Blood"},{"key":"1434_CR7","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1182\/blood-2006-08-038257","volume":"109","author":"LH Sehn","year":"2007","unstructured":"Sehn, L. H., Berry, B., Chhanabhai, M., Fitzgerald, C., Gill, K., Hoskins, P. et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 109, 1857\u20131861 (2007).","journal-title":"Blood"},{"key":"1434_CR8","doi-asserted-by":"publisher","first-page":"1264","DOI":"10.1038\/bjc.2016.325","volume":"115","author":"KT Prochazka","year":"2016","unstructured":"Prochazka, K. T., Melchardt, T., Posch, F., Schlick, K., Deutsch, A., Beham-Schmid, C. et al. NCCN-IPI score-independent prognostic potential of pretreatment uric acid levels for clinical outcome of diffuse large B-cell lymphoma patients. Br. J. Cancer 115, 1264\u20131272 (2016).","journal-title":"Br. J. Cancer"},{"key":"1434_CR9","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1111\/bjh.14489","volume":"176","author":"C Montalban","year":"2017","unstructured":"Montalban, C., Diaz-Lopez, A., Dlouhy, I., Rovira, J., Lopez-Guillmermo, A., Alonso, S. et al. Validation of the NCCN-IPI for diffuse large B-cell lymphoma (DLBCL): the addition of beta(2)-microglobulin yields a more accurate GELTAMO-IPI. Br. J. Haematol. 176, 918\u2013928 (2017).","journal-title":"Br. J. Haematol."},{"key":"1434_CR10","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","volume":"378","author":"R Schmitz","year":"2018","unstructured":"Schmitz, R., Wright, G. W., Huang, D. W., Johnson, C. A., Phelan, J. D., Wang, J. Q. et al. Genetics and pathogenesis of diffuse large B-cell lymphoma. N. Engl. J. Med. 378, 1396\u20131407 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1434_CR11","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B., Stewart, C., Dunford, A. J., Kim, J., Kamburov, A., Redd, R. A. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u2013690 (2018).","journal-title":"Nat. Med."},{"key":"1434_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-019-0403-7","author":"SY Oh","year":"2019","unstructured":"Oh, S. Y., Kim, W. S., Kim, J. S., Kim, S. J., Yoon, D. H., Yang, D. H. et al. Phase II study of R-CVP followed by rituximab maintenance therapy for patients with advanced marginal zone lymphoma: consortium for improving survival of lymphoma (CISL) study. Cancer Commun. https:\/\/doi.org\/10.1186\/s40880-019-0403-7 (2019).","journal-title":"Cancer Commun."},{"key":"1434_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.ccell.2020.03.015","volume":"37","author":"GW Wright","year":"2020","unstructured":"Wright, G. W., Huang, D. W., Phelan, J. D., Coulibaly, Z. A., Roulland, S., Young, R. M. et al. A probabilistic classification tool for genetic subtypes of diffuse large B cell lymphoma with therapeutic implications. Cancer Cell 37, 551\u2013568 (2020).","journal-title":"Cancer Cell"},{"key":"1434_CR14","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1002\/cac2.12073","volume":"40","author":"R Yang","year":"2020","unstructured":"Yang, R., Shao, T., Long, M., Shi, Y., Liu, Q., Yang, L. et al. Long noncoding RNA PVT1 promotes tumor growth and predicts poor prognosis in patients with diffuse large B-cell lymphoma. Cancer Commun. 40, 551\u2013555 (2020).","journal-title":"Cancer Commun."},{"key":"1434_CR15","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1093\/annonc\/mdp531","volume":"21","author":"A Bari","year":"2010","unstructured":"Bari, A., Marcheselli, L., Sacchi, S., Marcheselli, R., Pozzi, S., Ferri, P. et al. Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. Ann. Oncol. 21, 1486\u20131491 (2010).","journal-title":"Ann. Oncol."},{"key":"1434_CR16","doi-asserted-by":"publisher","first-page":"290","DOI":"10.1111\/bjh.14237","volume":"175","author":"Y Chen","year":"2016","unstructured":"Chen, Y., Neelapu, S., Feng, L., Bi, W., Yang, T.-H., Wang, M. et al. Prognostic significance of baseline peripheral absolute neutrophil, monocyte and serum 2-microglobulin level in patients with diffuse large b-cell lymphoma: a new prognostic model. Br. J. Haematol. 175, 290\u2013299 (2016).","journal-title":"Br. J. Haematol."},{"key":"1434_CR17","doi-asserted-by":"publisher","first-page":"440","DOI":"10.1002\/hon.2312","volume":"35","author":"Y Kanemasa","year":"2017","unstructured":"Kanemasa, Y., Shimoyama, T., Sasaki, Y., Tamura, M., Sawada, T., Omuro, Y. et al. Beta-2 microglobulin as a significant prognostic factor and a new risk model for patients with diffuse large B-cell lymphoma. Hematol. Oncol. 35, 440\u2013446 (2017).","journal-title":"Hematol. Oncol."},{"key":"1434_CR18","doi-asserted-by":"publisher","first-page":"2227","DOI":"10.1038\/sj.leu.2404780","volume":"21","author":"DH Kim","year":"2007","unstructured":"Kim, D. H., Baek, J. H., Chae, Y. S., Kim, Y. K., Kim, H. J., Park, Y. H. et al. Absolute lymphocyte counts predicts response to chemotherapy and survival in diffuse large B-cell lymphoma. Leukemia 21, 2227\u20132230 (2007).","journal-title":"Leukemia"},{"key":"1434_CR19","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2011.112","volume":"25","author":"RA Wilcox","year":"2011","unstructured":"Wilcox, R. A., Ristow, K., Habermann, T. M., Inwards, D. J., Micallef, I. N. M., Johnston, P. B. et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia 25, 1502\u20131509 (2011).","journal-title":"Leukemia"},{"key":"1434_CR20","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1182\/blood-2016-12-759621","volume":"130","author":"N Tsuyama","year":"2017","unstructured":"Tsuyama, N., Sakata, S., Baba, S., Mishima, Y., Nishimura, N., Ueda, K. et al. BCL2 expression in DLBCL: reappraisal of immunohistochemistry with new criteria for therapeutic biomarker evaluation. Blood 130, 489\u2013500 (2017).","journal-title":"Blood"},{"key":"1434_CR21","doi-asserted-by":"publisher","first-page":"3452","DOI":"10.1200\/JCO.2011.41.0985","volume":"30","author":"NA Johnson","year":"2012","unstructured":"Johnson, N. A., Slack, G. W., Savage, K. J., Connors, J. M., Ben-Neriah, S., Rogic, S. et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J. Clin. Oncol. 30, 3452\u20133459 (2012).","journal-title":"J. Clin. Oncol."},{"key":"1434_CR22","doi-asserted-by":"publisher","first-page":"4021","DOI":"10.1182\/blood-2012-10-460063","volume":"121","author":"S Hu","year":"2013","unstructured":"Hu, S., Xu-Monette, Z. Y., Tzankov, A., Green, T., Wu, L., Balasubramanyam, A. et al. MYC\/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program. Blood 121, 4021\u20134031 (2013).","journal-title":"Blood"},{"key":"1434_CR23","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1182\/blood.V99.3.815","volume":"99","author":"M Yamaguchi","year":"2002","unstructured":"Yamaguchi, M., Seto, M., Okamoto, M., Ichinohasama, R., Nakamura, N., Yoshino, T. et al. De novo CD5(+) diffuse large B-cell lymphoma: a clinicopathologic study of 109 patients. Blood 99, 815\u2013821 (2002).","journal-title":"Blood"},{"key":"1434_CR24","doi-asserted-by":"publisher","first-page":"2069","DOI":"10.1093\/annonc\/mdq057","volume":"21","author":"N Niitsu","year":"2010","unstructured":"Niitsu, N., Okamoto, M., Tamaru, J. I., Yoshino, T., Nakamura, N., Nakamura, S. et al. Clinicopathologic characteristics and treatment outcome of the addition of rituximab to chemotherapy for CD5-positive in comparison with CD5-negative diffuse large B-cell lymphoma. Ann. Oncol. 21, 2069\u20132074 (2010).","journal-title":"Ann. Oncol."},{"key":"1434_CR25","doi-asserted-by":"publisher","first-page":"2848","DOI":"10.1200\/JCO.2014.60.2383","volume":"33","author":"DW Scott","year":"2015","unstructured":"Scott, D. W., Mottok, A., Ennishi, D., Wright, G. W., Farinha, P., Ben-Neriah, S. et al. Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies. J. Clin. Oncol. 33, 2848\u20132856 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1434_CR26","doi-asserted-by":"publisher","first-page":"400","DOI":"10.1016\/j.blre.2018.03.005","volume":"32","author":"JC Wight","year":"2018","unstructured":"Wight, J. C., Chong, G., Grigg, A. P. & Hawkes, E. A. Prognostication of diffuse large B-cell lymphoma in the molecular era: moving beyond the IPI. Blood Rev. 32, 400\u2013415 (2018).","journal-title":"Blood Rev."},{"key":"1434_CR27","doi-asserted-by":"publisher","first-page":"2515","DOI":"10.1200\/JCO.2016.70.3660","volume":"35","author":"AM Staiger","year":"2017","unstructured":"Staiger, A. M., Ziepert, M., Horn, H., Scott, D. W., Barth, T. F. E., Bernd, H.-W. et al. Clinical impact of the cell-of-origin classification and the MYC\/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the German High-grade Non-Hodgkin\u2019s Lymphoma Study Group. J. Clin. Oncol. 35, 2515\u20132526 (2017).","journal-title":"J. Clin. Oncol."},{"key":"1434_CR28","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/leu.2015.44","volume":"29","author":"Y Yang","year":"2015","unstructured":"Yang, Y., Zhang, Y. J., Zhu, Y., Cao, J. Z., Yuan, Z. Y., Xu, L. M. et al. Prognostic nomogram for overall survival in previously untreated patients with extranodal NK\/T-cell lymphoma, nasal-type: a multicenter study. Leukemia 29, 1571\u20131577 (2015).","journal-title":"Leukemia"},{"key":"1434_CR29","doi-asserted-by":"publisher","first-page":"2454","DOI":"10.1038\/s41375-019-0466-0","volume":"33","author":"XP Tian","year":"2019","unstructured":"Tian, X. P., Huang, W. J., Huang, H. Q., Liu, Y. H., Wang, L., Zhang, X. et al. Prognostic and predictive value of a microRNA signature in adults with T-cell lymphoblastic lymphoma. Leukemia 33, 2454\u20132465 (2019).","journal-title":"Leukemia"},{"key":"1434_CR30","doi-asserted-by":"publisher","first-page":"861","DOI":"10.1200\/JCO.2014.56.6661","volume":"33","author":"W Liang","year":"2015","unstructured":"Liang, W., Zhang, L., Jiang, G., Wang, Q., Liu, L., Liu, D. et al. Development and validation of a nomogram for predicting survival in patients with resected non-small-cell lung cancer. J. Clin. Oncol. 33, 861\u2013869 (2015).","journal-title":"J. Clin. Oncol."},{"key":"1434_CR31","doi-asserted-by":"publisher","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","volume":"127","author":"SH Swerdlow","year":"2016","unstructured":"Swerdlow, S. H., Campo, E., Pileri, S. A., Harris, N. L., Stein, H., Siebert, R. et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood 127, 2375\u20132390 (2016).","journal-title":"Blood"},{"key":"1434_CR32","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","volume":"32","author":"BD Cheson","year":"2014","unstructured":"Cheson, B. D., Fisher, R. I., Barrington, S. F., Cavalli, F., Schwartz, L. H., Zucca, E. et al. Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification. J. Clin. Oncol. 32, 3059\u20133068 (2014).","journal-title":"J. Clin. Oncol."},{"key":"1434_CR33","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1093\/annonc\/mdt481","volume":"25","author":"L Weiss","year":"2014","unstructured":"Weiss, L., Melchardt, T., Habringer, S., Boekstegers, A., Hufnagl, C., Neureiter, D. et al. Increased body mass index is associated with improved overall survival in diffuse large B-cell lymphoma. Ann. Oncol. 25, 171\u2013176 (2014).","journal-title":"Ann. Oncol."},{"key":"1434_CR34","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1007\/s13277-012-0337-z","volume":"33","author":"Y Cao","year":"2012","unstructured":"Cao, Y., Shi, Y.-X., Chen, J.-O., Tan, Y.-T., Cai, Y.-C., Luo, H.-Y. et al. Serum C-reactive protein as an important prognostic variable in patients with diffuse large B cell lymphoma. Tumor Biol. 33, 1039\u20131044 (2012).","journal-title":"Tumor Biol."},{"key":"1434_CR35","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1093\/annonc\/mdn392","volume":"19","author":"D Ennishi","year":"2008","unstructured":"Ennishi, D., Takeuchi, K., Yokoyama, M., Asai, H., Mishima, Y., Terui, Y. et al. CD5 expression is potentially predictive of poor outcome among biomarkers in patients with diffuse large B-cell lymphoma receiving rituximab plus CHOP therapy. Ann. Oncol. 19, 1921\u20131926 (2008).","journal-title":"Ann. Oncol."},{"key":"1434_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1182\/blood-2003-05-1545","volume":"103","author":"CP Hans","year":"2004","unstructured":"Hans, C. P., Weisenburger, D. D., Greiner, T. C., Gascoyne, R. D., Delabie, J., Ott, G. et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103, 275\u2013282 (2004).","journal-title":"Blood"},{"key":"1434_CR37","doi-asserted-by":"publisher","first-page":"125","DOI":"10.3324\/haematol.2013.088161","volume":"99","author":"T Tadmor","year":"2014","unstructured":"Tadmor, T., Bari, A., Sacchi, S., Marcheselli, L., Liardo, E. V., Avivi, I. et al. Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: results from a large multicenter study involving 1191 patients in the pre- and post-rituximab era. Haematologica 99, 125\u2013130 (2014).","journal-title":"Haematologica"},{"key":"1434_CR38","doi-asserted-by":"publisher","first-page":"2563","DOI":"10.3109\/10428194.2015.1014367","volume":"56","author":"B Lin","year":"2015","unstructured":"Lin, B., Chen, C., Qian, Y. & Feng, J. Prognostic role of peripheral blood lymphocyte\/monocyte ratio at diagnosis in diffuse large B-cell lymphoma: a meta-analysis. Leuke Lymphoma 56, 2563\u20132568 (2015).","journal-title":"Leuke Lymphoma"},{"key":"1434_CR39","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.ejim.2014.01.019","volume":"25","author":"O Markovic","year":"2014","unstructured":"Markovic, O., Popovic, L., Marisavljevic, D., Jovanovic, D., Filipovic, B., Stanisavljevic, D. et al. Comparison of prognostic impact of absolute lymphocyte count, absolute monocyte count, absolute lymphocyte count\/absolute monocyte count prognostic score and ratio in patients with diffuse large B cell lymphoma. Eur. J. Intern. Med. 25, 296\u2013302 (2014).","journal-title":"Eur. J. Intern. Med."},{"key":"1434_CR40","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1016\/j.leukres.2014.03.013","volume":"38","author":"X Wei","year":"2014","unstructured":"Wei, X., Huang, F., Wei, Y., Jing, H., Xie, M., Hao, X. et al. Low lymphocyte-to-monocyte ratio predicts unfavorable prognosis in non-germinal center type diffuse large B-cell lymphoma. Leuke. Res. 38, 694\u2013698 (2014).","journal-title":"Leuke. Res."},{"key":"1434_CR41","first-page":"5","volume":"132","author":"F Morschhauser","year":"2019","unstructured":"Morschhauser, F., Feugier, P., Flinn, I. W., Gasiorowski, R. E., Greil, R., Illes, A. et al. Venetoclax plus rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R-CHOP) improves outcomes in BCL2-positive first-line diffuse large B-cell lymphoma (DLBCL): first safety, efficacy and biomarker analyses from the phase II CAVALLI study. Blood 132, 5 (2019). (abstract 782).","journal-title":"Blood"},{"key":"1434_CR42","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/35000501","volume":"403","author":"AA Alizadeh","year":"2000","unstructured":"Alizadeh, A. A., Eisen, M. B., Davis, R. E., Ma, C., Lossos, I. S., Rosenwald, A. et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 403, 503\u2013511 (2000).","journal-title":"Nature"},{"key":"1434_CR43","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1056\/NEJMoa012914","volume":"346","author":"A Rosenwald","year":"2002","unstructured":"Rosenwald, A., Wright, G., Chan, W. C., Connors, J. M., Campo, E., Fisher, R. I. et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N. Engl. J. Med. 346, 1937\u20131947 (2002).","journal-title":"N. Engl. J. Med."},{"key":"1434_CR44","doi-asserted-by":"publisher","DOI":"10.1186\/s40880-016-0150-y","author":"Q-Q Cai","year":"2016","unstructured":"Cai, Q.-Q., Hu, L.-Y., Geng, Q.-R., Chen, J., Lu, Z.-H., Rao, H.-L. et al. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study. Chin. J. Cancer https:\/\/doi.org\/10.1186\/s40880-016-0150-y (2016).","journal-title":"Chin. J. Cancer"},{"key":"1434_CR45","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1016\/j.tranon.2018.11.011","volume":"12","author":"Q Cai","year":"2019","unstructured":"Cai, Q., Fang, Y. & Young, K. H. Primary central nervous system lymphoma: molecular pathogenesis and advances in treatment. Transl. Oncol. 12, 523\u2013538 (2019).","journal-title":"Transl. Oncol."},{"key":"1434_CR46","doi-asserted-by":"publisher","first-page":"3150","DOI":"10.1200\/JCO.2015.65.6520","volume":"34","author":"N Schmitz","year":"2016","unstructured":"Schmitz, N., Zeynalova, S., Nickelsen, M., Kansara, R., Villa, D., Sehn, L. H. et al. CNS international prognostic index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP. J. Clin. Oncol. 34, 3150\u20133156 (2016).","journal-title":"J. Clin. Oncol."}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01434-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01434-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01434-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T15:16:46Z","timestamp":1658330206000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41416-021-01434-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,19]]},"references-count":46,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,8,3]]}},"alternative-id":["1434"],"URL":"https:\/\/doi.org\/10.1038\/s41416-021-01434-6","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,5,19]]},"assertion":[{"value":"12 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2021","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 April 2021","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Written informed content for all patients was provided. Ethical approval of the dataset used for this project was obtained from The Institutional Review Board of Sun Yat-sen University Cancer Center (Guangzhou, China, No. B2020\u2013235\u201301). The study was performed in accordance with the Declaration of Helsinki.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"No consent was involved in this publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to publish"}},{"value":"The authenticity of this article has been validated by uploading the key raw data onto the Research Data Deposit public platform (), with the approval RDD number as RDDA2020001739.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This work was supported by the National Natural Science Foundation of China (81672686), Special Support Program of Sun Yat-sen University Cancer Center (PT19020401), Science and Technology Planning Project of Guangzhou, China (202002030205) and Clinical Oncology Foundation of Chinese Society of Clinical Oncology (Y-XD2019\u2013124).","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding information"}}]}}